Save for later

Acomplia (rimonabant) suspended

The European Medicines Agency (EMEA) has recommended the suspension of the marketing authorisation for Acomplia (rimonabant), which was first authorised in Europe in 2006 to help overweight and obese people lose weight as an addition to diet and physical activity.

The EMEA’s Committee for Medicinal Products for Human Use (CHMP) has concluded that the benefits of Acomplia no longer outweigh its risks and the marketing authorisation should be suspended across the European Union. Warnings about psychiatric side effects, in particular depression, have been included in the product information since Acomplia was first authorised.

The EMEA is recommending healthcare professionals to stop prescribing the medication and people already taking it should consult their doctor as soon as possible.

Brand Icons/Telephone check - FontAwesome icons/tick icons/uk